Immunic Inc Stock Price, News & Analysis

Immunic, Inc. (Nasdaq: IMUX) announced promising results from its phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) for treating relapsing-remitting multiple sclerosis (RRMS). The drug demonstrated a low rate of confirmed disability worsening (1.6%) compared to 3.7% in the placebo group over a 24-week period. Long-term treatment showed 97.6% of patients free from disability worsening after 48 weeks. The company anticipates further data from its phase 3 ENSURE program and phase 2 CALLIPER trial in 2023, highlighting the drug's potential through its neuroprotective and anti-inflammatory effects.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, will participate in several investor and scientific conferences during November and December 2022. Key events include:

• November 17: A webcast discussing multiple sclerosis research and vidofludimus calcium development at 11:00 am ET.
• December 1: Fireside chat at the Piper Sandler Healthcare Conference at 12:30 pm ET.
• November 29 - December 2: Presentations at various conferences, including a poster on IMU-856 in Perth, Australia.

For more details, visit www.imux.com.

Immunic, Inc. (Nasdaq: IMUX) reported a net loss of approximately $21.2 million for Q3 2022, a loss of $0.69 per share, compared to $19.3 million the previous year. Cash and equivalents totaled $72.8 million as of September 30, 2022, bolstered by a $60 million private placement in October. The interim analysis of the phase 1b trial for IMU-935 in psoriasis showed no significant benefit over placebo. Despite this, Immunic remains optimistic about the drug's potential. They also reported positive results for IMU-856 and are advancing their phase 2 CALLIPER trial for IMU-838 in multiple sclerosis.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, will announce its financial results for Q3 2022 on November 3, 2022, before U.S. market opening. The announcement will include a corporate update, followed by a webcast at 8:00 am ET. Immunic is focused on developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, with key products in its pipeline, including IMU-838 for multiple sclerosis and IMU-935 targeting psoriasis.

Immunic, Inc. (Nasdaq: IMUX) announced the results of an interim analysis from its Phase 1b clinical trial of IMU-935 for moderate-to-severe psoriasis. The analysis revealed that the treatment arms did not significantly outperform a high placebo response at four weeks. While no new safety signals were identified, the unexpected high placebo rates were disappointing and will require further investigation. Despite this, the company remains optimistic about IMU-935's potential and will continue its development, with cash reserves expected to fund operations into Q4 2024.

Immunic, Inc. (Nasdaq: IMUX) announced a $60 million PIPE financing agreement to issue 8,696,552 shares at $4.35 per share and 5,096,552 Pre-Funded Warrants at $4.34 each. The deal, with participation from notable investors, is set to close on October 12, 2022. Proceeds will fund clinical development for leading candidates IMU-838, IMU-935, and IMU-856, enhancing Immunic's pipeline for chronic inflammatory and autoimmune diseases. The company also anticipates initial clinical activity data for IMU-935 in psoriasis later this month.

Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focusing on oral immunology therapies for chronic inflammatory diseases, will participate in several conferences in October 2022. Key events include the 30th UEG Week in Vienna (Oct 8-11), where its clinical team will attend; the International Celiac Disease Symposium in Italy (Oct 19-22), featuring a presentation on IMU-856; and BIO-Europe 2022 in Leipzig (Oct 24-26). Additionally, data from the phase 2 trial of vidofludimus calcium (IMU-838) will be presented at ECTRIMS in Amsterdam (Oct 26-28). More details can be found on their website.

Immunic, Inc. (Nasdaq: IMUX) announced favorable results from its Phase 1 clinical trial of IMU-856, indicating a positive safety, tolerability, and pharmacokinetic profile. The trial included single ascending doses (SAD) and multiple ascending doses (MAD) in healthy subjects, where no maximum tolerated dose was reached, and no serious adverse events occurred. The trial is ongoing with patients suffering from celiac disease. Results showed stable plasma concentrations and support the potential of IMU-856 as a first-in-class oral therapy for celiac disease and other gastrointestinal conditions.

Immunic, Inc. (Nasdaq: IMUX) announced its participation in several investor conferences throughout September 2022. Key events include the Citi's 17th Annual BioPharma Conference on September 7-8 in Boston, where CEO Daniel Vitt and Head of Investor Relations Jessica Breu will attend. The Wells Fargo 2022 Healthcare Conference will feature Dr. Vitt in a fireside chat on September 9 at 9:45 am EDT, with a live broadcast available on the company's website. Additionally, Breu will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29 at 1:00 pm EDT in New York.